Effect of Intravitreal Bevacizumab on Corneal Endothelium
- Conditions
- Corneal Endothelial Cell Loss
- Registration Number
- NCT01726790
- Lead Sponsor
- Khon Kaen University
- Brief Summary
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
- Detailed Description
Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 37
- aged between 20 and 80 years old
- can come to regular follow up at 6 month
- signed written consent forms
- not have corneal scar, or glaucoma
- history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit
- high risk in cerebrovascular and cardiovascular diseases
- Pregnancy and breastfeeding
- can undergo confocal microspopy
- History of intraocular surgery or ocular trauma during study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Corneal endothelium cell change after intravitreal Bevacizumab injection 6 months Measure the corneal endothelium cell using Confoscan4-Corneal confocal microscope in patient in retinal vascular clinic before and after treat with intravitreal Bevacizumab
- Secondary Outcome Measures
Name Time Method Assess the complication after intravitreal Bevacizumab injection 6 month
Trial Locations
- Locations (1)
KKU eye center, department of Ophthalmolgy, faculty of medicine, khon kaen university
🇹🇭Khon kaen, Thailand